Marshall Edwards (MSHL)
Marshall Edwards Liabilities: 1.499M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
MSHL Liabilities Rankings
| Overall | 98th percentile | 49 of 4390 |
| Sector | 97th percentile | 12 of 504 in Healthcare |
| Industry | 97th percentile | 1 of 39 in Drug Manufacturers - Other |
MSHL Liabilities Range, Past 5 Years
| Minimum | 1.296M | Dec 2011 |
| Maximum | 4.143M | Jun 2009 |
| Average | 2.425M |
About Total Liabilities
Liabilities are obligations of a company arising from past transactions or events which are expected to reduce assets when they are settled.
Total liabilities is a line item on the balance sheet.
Learn More
You may also be interested in these MSHL related companies
MSHL News
RT @Bud_Stocks LONG $PGNX and $MSHL and watching $CYCC if it breaks .57 with power Im long there to .63 then reevaluate. posted on the 27th
about 17 hours ago by Bud_Stocks
about 17 hours ago by Bud_Stocks
@Bud_Stocks $MSHL ..Sounds like a good idea. I did teh same with $EGT. Sold at the top. Waited for a pullback and repurchased.
about 3 days ago by Urbane_Gorilla
about 3 days ago by Urbane_Gorilla
@Bud_Stocks You're right about the longer term Fibs. I don't like sitting on anything that long. But $MSHL experiences a monthly 20-30% pop
about 3 days ago by Urbane_Gorilla
about 3 days ago by Urbane_Gorilla
LONG $PGNX and $MSHL and watching $CYCC if it breaks .57 with power Im long there to .63 then reevaluate
about 3 days ago by Bud_Stocks
about 3 days ago by Bud_Stocks
@Bud_Stocks I'll be buying $MSHL on Tuesday.. It'd be nice if it rocketed to 3.00 ..LOL!
about 3 days ago by Urbane_Gorilla
about 3 days ago by Urbane_Gorilla
@Bud_Stocks Re $MSHL ...I didn't check long term....Just looking for the short term ASCO pop. If it reverses it could easily go to 3.00
about 3 days ago by Urbane_Gorilla
about 3 days ago by Urbane_Gorilla
Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering
May 08, 9:03AM Benzinga
May 08, 9:03AM Benzinga
@STRONG_STOCK Wow, $MSHL was a $ 120+ stock back in 2004. Musta had some good stuff!
about 32 days ago by Bleedblue
about 32 days ago by Bleedblue
Ceradyne, San Juan Basin Royalty Among Stocks falling to Annual Lows Wednesday
Apr 25, 4:32PM Fox Business
Apr 25, 4:32PM Fox Business
Marshall Edwards Issued New Patent For Use Of Lead Drug Candidate ME-143 In Treating Cancer
Apr 25, 9:03AM Benzinga
Apr 25, 9:03AM Benzinga
$MSHL Receives FDA Approval of New Drug Application for Clinical Testing of Oncology Drug Candidate ME-344 http://stks.co/3Hv3
about 50 days ago by abubnic
about 50 days ago by abubnic
Marshall Edwards (MSHL) Gets FDA Approval for Mitochondrial Inhibitor ME-344
Apr 10, 9:04AM Street Insider
Apr 10, 9:04AM Street Insider
Marshall Edwards Receives Notice of Effectiveness for Rights Offering to Stockholders
Mar 27, 9:07AM Benzinga
Mar 27, 9:07AM Benzinga
Marshall Edwards (MSHL) Submits IND to FDA for ME-344; Commences 4th Cohort ME-143 Phase I Dosing
Mar 06, 9:09AM Street Insider
Mar 06, 9:09AM Street Insider
Marshall Edwards Submits Investigational New Drug Application for Oncology Drug Candidate ME-344
Mar 06, 9:00AM Benzinga
Mar 06, 9:00AM Benzinga
Marshall Edwards CEO to Present at Roth Capital Partners Growth Stock Conference
Feb 29, 9:00AM PR Newswire
Feb 29, 9:00AM PR Newswire
Marshall Edwards (MSHL) Announces Plans to Offer $8 Million in Common Stock to Shareholders
Feb 21, 9:05AM Street Insider
Feb 21, 9:05AM Street Insider
$MSHL filed latest Quarterly Report http://marketbrief.com/mshl/10q/quarterly-report/2012/2/9/9227612?s=st
about 112 days ago by MarketBrief
about 112 days ago by MarketBrief
Small cancer bios hot today. $SNSS starting. $MSHL, $AGEN, $ENMD already went.
about 125 days ago by GarethSoloway
about 125 days ago by GarethSoloway
Marshall Edwards (MSHL) Receives New Method of Use Patent for ME-344 in Treatment of Cancer
Jan 03, 9:08AM Street Insider
Jan 03, 9:08AM Street Insider
Marshall Edwards Issued New Method of Use Patent for Lead Oncology Drug Candidate ME-344
Jan 03, 9:00AM PR Newswire
Jan 03, 9:00AM PR Newswire
Marshall Edwards Awarded Key Patent For Compositions Of Lead Oncology Drug Candidates
Dec 20, 9:08AM Benzinga
Dec 20, 9:08AM Benzinga
Marshall Edwards CEO to Present at Lazard Capital Markets Healthcare Conference
Nov 10, 9:00AM PR Newswire
Nov 10, 9:00AM PR Newswire
$MSHL filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/rGZ
about 215 days ago by MarketBrief
about 215 days ago by MarketBrief
Marshall Edwards and Ausio Pharmaceuticals sign exclusive license agreement
Oct 27, 9:11AM FlyOnTheWall
Oct 27, 9:11AM FlyOnTheWall
Marshall Edwards and Ausio Pharmaceuticals Announce Exclusive License Agreement
Oct 27, 9:00AM PR Newswire
Oct 27, 9:00AM PR Newswire
Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors
Oct 24, 9:00AM PR Newswire
Oct 24, 9:00AM PR Newswire
Reminder: Marshall Edwards to Host Conference Call on Thursday, September 29
Sep 27, 9:00AM PR Newswire
Sep 27, 9:00AM PR Newswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| MSHL | 0.66 | +0.04 | +6.43% | 9.682M |
| MSG | 37.63 | +0.06 | +0.16% | 2.337B |
| MSFT | 29.32 | -0.24 | -0.81% | 248.03B |
| MSFG | 11.10 | -0.06 | -0.54% | 225.66M |
| MSF | 13.23 | -0.21 | -1.56% | |
| MSEX | 18.14 | -0.05 | -0.27% | 285.58M |
| MSD | 10.77 | -0.05 | -0.46% | |
| MSCI | 34.22 | -0.43 | -1.24% | 4.209B |
| MSCC | 18.00 | -0.49 | -2.65% | 1.617B |
| MSB | 24.80 | -0.46 | -1.82% | 331.41M |